PRQR ProQR Therapeutics N.V.
Healthcare$1.58+0.00%OpenMarket Cap: $167.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.75
P/S
10.51
EV/EBITDA
-1.70
DCF Value
$-41.14
FCF Yield
-34.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
-345.5%
Net Margin
-339.4%
ROE
-86.5%
ROA
-46.0%
ROIC
-67.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.1M | 65.9% | $-13.9M | $-13.6M | $— | — |
| Q4 null | $4.6M | 85.5% | $-9.0M | $-8.8M | $— | — |
| FY null | $15.3M | 83.0% | $-42.2M | $-40.5M | $— | — |
| Q3 null | $2.9M | 100.0% | $-11.3M | $-11.0M | $— | — |
| Q2 null | $3.8M | 100.0% | $-12.2M | $-12.2M | $— | — |
| Q1 null | $4.5M | 100.0% | $-10.8M | $-10.1M | $— | — |
| Q4 null | $4.3M | 100.0% | $-10.1M | $-9.3M | $— | — |
| FY null | $18.9M | 100.0% | $-30.5M | $-27.8M | $— | — |
| Q3 null | $3.8M | 100.0% | $-8.7M | $-8.1M | $— | — |
| Q2 null | $6.3M | 100.0% | $-3.6M | $-2.7M | $— | — |
| Q1 null | $4.5M | 100.0% | $-8.1M | $-7.7M | $— | — |
| Q4 2023 | $3.3M | 100.0% | $-6.3M | $-5.5M | $-0.07 | — |